Next-generation polymerized human hemoglobins in hepatic bioreactor simulations

Clayton Cuddington1 | Savannah Moses1 | Donald Belcher1 | Niral Ramesh2 | Andre Palmer1

1Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio
2Department of Chemical and Biomolecular Engineering, Rice University, Houston, Texas

Correspondence
Andre Palmer, Department of Chemical and Biomolecular Engineering, The Ohio State University, 151 W. Woodruff Ave., Columbus, OH 43210.
Email: palmer.351@osu.edu

Funding information
National Institutes of Health, Grant/Award Numbers: R01EB021926, R01HL126945, R01HL138116; U.S. Department of Defense, Grant/Award Number: W81XWH-18-1-0059

Peer Review
The peer review history for this article is available at https://publons.com/publon/10.1002/btpr.2958.

Abstract
Hepatic hollow fiber (HF) bioreactors can be used to provide temporary support to patients experiencing liver failure. Before being connected to the patient's circulation, cells in the bioreactor must be exposed to a range of physiological O2 concentrations as observed in the liver sinusoid to ensure proper performance. This zonation in cellular oxygenation promotes differences in hepatocyte phenotype and may better approximate the performance of a real liver within the bioreactor. Polymerized human hemoglobin (PolyhHb) locked in the tense quaternary state (T-state) has the potential to both supply and regulate O2 transport to cultured hepatocytes in the bioreactor due to its low O2 affinity. In this study, T-state PolyhHb production and purification processes were optimized to minimize the concentration of low-molecular-weight PolyhHb species in solution. Deconvolution of size-exclusion chromatography spectra was performed to calculate the distribution of polymeric Hb species in the final product. Fluid flow and mass transport within a single fiber of a hepatic HF bioreactor was computationally modeled with finite element methods to simulate the effects of employing T-state PolyhHb to facilitate O2 transport in a hepatic bioreactor system. Optimal bioreactor performance was defined as having a combined hypoxic and hyperoxic volume fraction in the extracapillary space of less than 0.05 where multiple zones were observed. The Damköhler number and Sherwood number had strong inverse relationships at each cell density and fiber thickness combination. These results suggest that targeting a specific Damköhler number may be beneficial for optimal hepatic HF bioreactor operation.

KEYWORDS
fluid flow modeling, hemoglobin-based oxygen carrier, hollow fiber bioreactor, polymerized human hemoglobin, red blood cell substitute

https://doi.org/10.1002/btpr.2958
1 | INTRODUCTION

Hepatic hollow fiber (HF) bioreactors have the potential to support patients who are suffering from acute liver failure.\(^1\) Cell culture media used to provide nutrients to hepatocytes in HF bioreactors must be supplemented with an oxygen (O\(_2\)) carrier in order to provide O\(_2\) offloading ability. To date, there is no practical O\(_2\) carrier for use in HF bioreactors such as those employed as a bioartificial liver assist devices.\(^2\) Because red blood cells (RBCs) undergo hemolysis in these devices, blood is an ineffective choice for use as an O\(_2\) carrier in the perfusate.\(^3\) Therefore, the goal of this work is to create a perfusate that can adequately oxygenate the high cell density found in the extracapillary space (ECS) of HF bioreactors. Given that hemoglobin (Hb) is the natural O\(_2\) transport molecule in vivo,\(^4\) Hb is a potential choice for improving O\(_2\) transport in an HF bioreactor. However, the small size of Hb [molecular weight (MW) of 64 kDa and an effective diameter of 5 nm] limits its application in a perfusate solution.\(^5\) This free protein, as well as other low MW Hb species (<500 kDa), are small enough to extravasate through the membrane in the HF bioreactor. After extravasating into the ECS, Hb can come in to direct contact with cells residing in the ECS. When in direct contact with the cells in the ECS, the reactive O\(_2\) species generated by unmodified Hb result in oxidative tissue damage and cell death.\(^6,7\)

To prevent these harmful effects, Hb can be modified to create an Hb-based O\(_2\) carrier (HBOC).\(^8,9\) HBOCs are a promising class of RBC substitute. Popular forms of Hb modification include PEGylation, surface conjugation, encapsulation, and polymerization.\(^10,11\) Of these, polymerized Hb (PolyHb) is the most viable due to its low cost and scalability.\(^11\) Polymerization of Hb with glutaraldehyde as a nonspecific crosslinker is a common strategy used in the synthesis of previous generations of PolyHbs.\(^12\) However, these earlier generation PolyHbs were not effective because they contained large amounts of free Hb and other low MW polymeric Hb species.\(^13-15\)

Previous studies have shown that the average size of PolyHb can be altered by varying the molar ratio of glutaraldehyde to Hb. While this modification increases the average MW of PolyHb, it does not eliminate the presence of low MW polymeric Hb species.\(^16,17\) To address this issue, a two-stage tangential flow filtration (TFF) system can be employed.\(^18,19\) The product is first passed through a 0.2 μm TFF filter cartridge to remove large PolyHb aggregates. It is then dialyzed over a TFF filter cartridge with MW cutoff on the order of hundreds of kDa to remove as much low MW PolyHb as possible. The final PolyHb product would then have a viable MW distribution for use in bioreactor or ex vivo organ circuits.

The primary drawback of hepatic HF bioreactors is insufficient O\(_2\) transport to support a high density of hepatocytes in the ECS.\(^20,21\) Ideally, O\(_2\) transport across the membrane would be regulated to mirror the hepatic O\(_2\) gradient observed in vivo. Prior research has demonstrated that polymerized human Hb (PolyHB) frozen in the tense quaternary state (T-state) can regulate O\(_2\) transport to cells housed in the ECS.\(^17\) This can prevent the development of hypoxia and hyperoxia, allowing the hepatocytes to function more effectively. Additionally, hepatic cells must be exposed to a range of physiological O\(_2\) concentrations as observed in the liver sinusoid, which is known as zonation, to properly function.\(^1,22\)

This study builds on previous work and explores a method of quantifying zonation as well as general bioreactor performance. The HF length, single capillary system radius, perfusate flow rate, inlet O\(_2\) partial pressure (pO\(_2\)in), HBOC concentration, and cell density were varied to determine their effect on bioreactor operation. Two dimensionless numbers, the Damköhler number and Sherwood number, were calculated within the bioreactor system, and their relationship to overall bioreactor performance and zonation was evaluated. The primary objective was to determine which variables and dimensionless numbers strongly correlate to bioreactor performance and zonation.

2 | MATERIALS AND METHODS

2.1 | Materials

Glutaraldehyde (70%), sodium chloride (NaCl), potassium chloride (KCl), sodium hydroxide (NaOH), sodium dithionite (Na\(_2\)S\(_2\)O\(_4\)), calcium chloride (CaCl\(_2\)·2H\(_2\)O), sodium lactate, N-acetyl-L-cysteine (NALC), sodium cyanoborohydride (NaCNBH\(_3\)), sodium phosphate dibasic (Na\(_2\)HPO\(_4\)), and sodium phosphate monobasic (NaH\(_2\)PO\(_4\)) were purchased from Sigma-Aldrich (St. Louis, MO). HF TFF modules (PES 0.2 μm and PS 500 kDa) were purchased from Spectrum Laboratories (Rancho Dominguez, CA). All other chemicals were purchased from Fisher Scientific (Pittsburgh, PA). Expired human RBC units were generously donated by Transfusion Services, Wexner Medical Center, The Ohio State University, Columbus, OH.

2.2 | PolyhHb synthesis

Human hemoglobin (Hb) was first purified via TFF as described by Palmer et al.\(^23\) Glutaraldehyde was used as the crosslinking agent at a 30:1 molar ratio of glutaraldehyde to Hb as described previously.\(^24,25\)

The hHb was diluted to 40 ± 5 g/L in phosphate-buffered saline (PBS) (0.1 M, pH 7.4) and filtered through a 0.2 μm polysulfone (PS) TFF module to remove any large aggregates formed during cryogenic storage.

The hHb was further diluted with PBS to a total working volume of 1,500 ml at a concentration of 19.5 ± 1 g/L. The solution was then added to an airtight glass reaction vessel. The solution was mixed continuously with a stir bar and constant temperature was maintained by placing the reaction vessel in a water bath at 37°C. The hHb solution was deoxygenated via continuous recirculation through a 3M MiniModule gas exchange membrane (Maplewood, MN). The solution partial pressure of dissolved O\(_2\) (pO\(_2\)) was verified on a Rapidlab 248 (Siemens, Malvern, PA) blood gas analyzer (BGA). Once the pO\(_2\) was below 10 mmHg, Na\(_2\)S\(_2\)O\(_4\) was used to remove the remaining O\(_2\) dissolved in solution. An initial bolus addition of 300 mg was dissolved in 50 ml PBS sparged with...
nitrogen (N₂), followed by four 50 mg additions in 1 ml deoxygenated PBS over 15 min intervals. A final BGA reading was taken to ensure the pO₂ was below detectable levels (<0 mmHg).

A 30:1 molar ratio of glutaraldehyde to hHb was then added to the reactor at 2 ml/min using a syringe pump (New Era Pump Systems, Farmingdale, NY). After the glutaraldehyde addition was completed, the solution was allowed to polymerize for 2 hr under positive N₂ pressure in the reactor headspace.

The polymerization reaction was then quenched at ambient temperature (20°C) with a 7:1 molar ratio NaCNBH₃ to glutaraldehyde. The addition of NaCNBH₃ also reduces the Schiff bases in solution and minimizes methemoglobin (metHb) levels in the final product. The PolyhHb solution was quenched at ambient temperature for 30 min and then the vessel was stored at 4°C overnight.

2.3 PolyhHb purification and diafiltration

All purification steps took place in a 4°C refrigerator. The PolyhHb solution was first passed through a 0.2 μm PS TFF cartridge to remove large polymeric Hb species from the solution. Diafiltration over a 500 kDa TFF cartridge then removed low MW polymeric Hb species, unpolymerized hHb, and unreacted glutaraldehyde. The diafiltration occurs simultaneously with an exchangeant between physiological conditions. The same protocol was repeated for hHb as a control for metHb levels over time.

2.4 Oxygen equilibrium measurements

O₂ equilibrium curves (OEC) for hHb and PolyhHb were measured using a HemoX Analyzer (TCS Scientific Corp., New Hope, PA) at 37°C (physiological temperature). The O₂ binding data from these experiments were fit to the Hill equation to regress the resultant partial pressure of O₂ at which 50% of the hHb or PolyhHb is saturated with O₂ (P₅₀) and cooperativity coefficient (n).

2.5 Size-exclusion chromatography

High-performance liquid chromatography (HPLC) coupled with size-exclusion chromatography (SEC) was performed with an Ultimate 3000 system using an SEC-1000 column (ThermoFisher Scientific, Waltham, MA). The absorbance was measured at 412 nm to monitor the Soret peak of Hb in the sample. The resultant intensity versus time data was scaled such that the maximum intensity for each run was set to 1. These data were then used to determine the size and MW of the PolyhHbs.

2.5.1 Spectral deconvolution

SEC data were analyzed using a novel computational program in RStudio (Version 1.1.456, RStudio, Inc., Boston, MA). PolyhHbs of different sizes were characterized by their “polymer order” (nₒ), which corresponds to how many times the Hb polymer doubled in size to reach its current mass. This was defined as

$$N_{Hb} = 2^{n_{o}}, \quad (1)$$

where \(N_{Hb}\) is the number of hHb tetramers in the Hb polymer.

Since the MW of a single hHb tetramer is 64 kDa, Equation (1) was scaled to

$$MW_{Polymer} (kDa) = 64 \times 2^{n_{o}}, \quad (2)$$

such that a zeroth-order polymer (unpolymerized hHb) corresponds to 1 hHb tetramer in Equation (1) and 64 kDa in Equation (2).

The SEC elution time was calibrated to hHb according to the equation

$$MW(Da) = 10^{-0.7339 \times \text{elution time} + 11.855}. \quad (3)$$

Equations (2) and (3) were combined to determine the elution times of the various polymer orders. Gaussian curves at each polymer order elution time were scaled to fit the total elution curve of the PolyhHb mixture. The scaled normal curves of the polymeric Hb species were used to calculate the fraction of each polymer order in the final PolyhHb product.

2.6 Auto-oxidation

A representative sample of 30:1 T-state PolyhHb was removed from cryogenic storage and allowed to thaw. The sample was then diluted to 12.5 mg/ml, which corresponds to a typical HBOC concentration in the circulation immediately after transfusion as well as the primary PolyhHb concentration in the bioreactor simulations. The 630 nm peak of the sample was monitored over 24 hr by UV–vis spectrometry. The cuvette was kept at 37°C to replicate physiological conditions. The same protocol was repeated for hHb as a control for metHb levels over time.

2.7 Model hepatic HF bioreactor

For this model, we computationally examined a single fiber of a hepatic HF bioreactor utilizing T-state PolyhHb as the O₂ carrier, which is shown in Figure 1. Both fluid flow and O₂ mass transport
with reactions were computationally modeled using finite element methods in COMSOL Multiphysics version 5.3a (COMSOL Inc., Burlington MA). The model physics are unchanged from a recent publication.\textsuperscript{17} The HF radius, fiber length, flow rate, inlet O\textsubscript{2} concentration, cell density, and PolyhHb concentration were each varied to evaluate preferred bioreactor operating conditions.

2.8 | Dimensionless numbers

To assess PolyhHb-mediated mass transfer of O\textsubscript{2} from the HF lumen into the ECS, we examined the Sherwood number, also known as the mass-transfer Nusselt number, which is calculated as shown below.

\[
Sh = \frac{k_c 2R_{\text{lumen}}}{D_{O_2}},
\]

where \(R_{\text{lumen}}\) is the outer radius of the lumen, \(D_{O_2}\) is the diffusivity of O\textsubscript{2} in the lumen, and \(k_c\) is the mass transfer coefficient, which was calculated as follows:

\[
k_c = \frac{J_{O_2}}{[O_2]_{\text{lumen}} - [O_2]_{\text{ECS}}},
\]

To relate how the O\textsubscript{2} consumption rate (OCR) by the cells in the ECS compared to the residence time in the system, we used a theoretical form of the Damköhler number \([\text{Damköhler number (Da)}_{\text{theor}}]\) as shown below.

\[
Da_{\text{theor}} = \frac{\text{OCR}}{[O_2]_{\text{ECS}}},
\]

where \([O_2]_{\text{ECS}}\) is the concentration of O\textsubscript{2} in the ECS, and the residence time is defined as follows:

\[
\text{Residence time} = \tau = \frac{V_{\text{ECS}}}{Q_{\text{in}}},
\]

where \(V_{\text{ECS}}\) is the volume of the ECS and \(Q_{\text{in}}\) is the total volumetric flow rate of PolyhHb supplemented media in the system. The OCR of cells in the ECS is calculated by evaluating the net concentration of O\textsubscript{2} entering the HF (accounting for both dissolved O\textsubscript{2} and Hb bound O\textsubscript{2}) divided by the residence time.

\[
\text{OCR} = \frac{[\text{HbO}_2]_{\text{in}} - [\text{HbO}_2]_{\text{out}} + [O_2]_{\text{in}} - [O_2]_{\text{out}}}{\tau},
\]

Unfortunately, the theoretical Damköhler number uses the average ECS O\textsubscript{2} concentration, which is difficult to measure within the bulk of large HF modules that can contain bundles of more than 1,000 fibers. Because of this limitation, we also define a practical Damköhler \([\text{Da}_{\text{pract}}]\) number that uses the average of the inlet and outlet O\textsubscript{2} concentrations as an approximation. Since the latter is more straightforward to measure during the experimental operation of the bioreactor, it is primarily presented in our analysis.

\[
\text{Da}_{\text{pract}} = \frac{2\tau \cdot \text{OCR}}{[O_2]_{\text{in}} + [O_2]_{\text{out}}},
\]

2.9 | Zonation

The bioreactor volume is divided into five zones based on the pO\textsubscript{2} present. The thresholds for each zone are given below:

- (a) (b)
- (c)
Hypoxic (H) = $pO_2 < 20\text{mmHg}$.

Perivenous (Pv) = $20\text{mmHg} < pO_2 < 35\text{mmHg}$.

Pericentral (Pc) = $35\text{mmHg} < pO_2 < 60\text{mmHg}$.

Periportal (Pp) = $60\text{mmHg} < pO_2 < 70\text{mmHg}$.

Hyperoxic (Hr) = $pO_2 > 70\text{mmHg}$.

For these simulations, we considered situations where the zonation was balanced between the perivenous, pericentral, and periportal regions. To quantify when this kind of zonation occurred, we calculated a zonation score (Z) by dividing the average absolute deviation of the perivenous, pericentral, and periportal volume fractions divided by the sum of the perivenous, pericentral, and periportal volume fraction.

$$Z = \frac{\sum\limits_{i} n_i | V_{f,i} - n_i^{-1} \sum\limits_{i} n_i V_{f,i} |}{n_i \cdot \sum\limits_{i} V_{f,i}},$$

where $V_{f,i}$ is the volume of the ith zone, and $n_i$ is the total number of zones considered. For our model, we only considered pericentral, perivenous, and periportal regions so $n_i$ was set to 3.

3 | RESULTS AND DISCUSSION

There are multiple biophysical metrics to assess the efficacy of PolyhHb as an HBOC. Table 1 shows the concentration (C), metHb level, hydrodynamic diameter of PolyhHb ($D_{PolyhHb}$), MW, $P_{SO}$, $n$, and rate constant of auto-oxidation ($k_{ox}$) for both 30:1 T-state PolyhHb and unmodified hHb.

### 3.1 | Protein concentrations

The 30:1 T-state PolyhHb produced was concentrated to 10.1 ± 0.6 g/dl. This concentration is comparable to previous commercial HBOCs: PolyHeme 10 g/dl\textsuperscript{31} and Hemolink 9.7 g/dl\textsuperscript{32}.

| Species            | hHb    | 30:1 T-state PolyhHb |
|--------------------|--------|----------------------|
| C (g/dl)           | 21 ± 5 | 10.1 ± 0.6           |
| metHb (%)          | 2.0 ± 0.6 | 5.7 ± 1.6         |
| $D_{PolyhHb}$ (nm) | 5.5 34 | 45 ± 6              |
| MW (kDa)           | 64 ± 2 | 1.300 ± 100         |
| $P_{SO}$ (mmHg)    | 12.8 ± 0.1 | 41 ± 3            |
| $n$                | 2.9 ± 0.1 | 1.0 ± 0.1          |
| $k_{ox}$ (h$^{-1}$)| 0.0432 ± 0.001 | 0.0261 ± 0.006   |

The metHb level of the final PolyhHb was more than double that of unmodified hHb. This can be explained by two different steps in the synthesis procedure. During polymerization, hHb in the reactor was maintained at 37°C for approximately 2 hr. While the reaction was eventually quenched with NaCNBH\textsubscript{3}, which reduces metHb in solution, there was still an increase in the metHb level at this step. Additionally, previous studies have shown that there is auto-oxidation that occurs during TFF purification leading to further increases in the metHb level.\textsuperscript{33,34} Decreasing the temperature during TFF can lead to less metHb formation, so the solution temperature during TFF was reduced from 4°C to approximately 0°C by submerging the purification vessels in ice. The resultant metHb levels fell from 6.76 ± 1.3% to 4.69 ± 1.1% confirming that TFF processing increases metHb levels above that of unmodified hHb. The metHb levels were similar between 30:1 T-state PolyhHb and commercial HBOCs. The biophysical properties of some previous generation HBOCs are shown in Table 2.

3.2 | Hydrodynamic diameter of PolyhHb

The $D_{PolyhHb}$ of 30:1 T-state PolyhHb (45 ± 11 nm) is significantly larger ($p < .05$) than the reported diameter of free Hb, 5.5 nm.\textsuperscript{34} The increased diameter of PolyhHb will help mitigate the negative side effects associated with free Hb in a bioreactor such as free heme release, extravasation to the cells in the ECS, and oxidative tissue damage.\textsuperscript{35}

3.3 | Oxygen equilibrium

The $O_2$-Hb binding data were fit to the Hill equation. The resulting data and fit are shown in Figure 2. From this fit, the $P_{SO}$ and $n$ were determined. The differences between the $P_{SO}$ and cooperativity in hHb and PolyhHb are shown to be statistically significant. The 30:1 T-state $O_2$-PolyhHb binding curve is not sigmoidal, unlike the $O_2$-Hb binding curve. The absence of sigmoidal $O_2$ binding represents a loss of cooperativity after Hb is cross-linked. Cooperativity is a function of the quaternary structure of the Hb protein. After being locked in the T-state, the quaternary structure is unable to change, and consequently, cooperativity is lost in PolyhHBs.\textsuperscript{36}

The other notable change that results from polymerizing deoxygenated Hb is the right shift in the $P_{SO}$. Polymerization restricts the resultant PolyhHb to the T-state conformation.\textsuperscript{37} The right shift in the OEC corresponds to a lower $O_2$ affinity and a greater $O_2$ offloading ability. This increased $O_2$ offloading potential is vital for optimal bioreactor function as it allows oxygenation across physiologically relevant $O_2$ tensions. The $P_{SO}$ of T-state PolyhHb is comparable to the $P_{SO}$ of Oxyglobin, Hemopure (Biopure Corp., Cambridge, MA), and Hemolink (Hemosol Inc., Toronto, Canada), yet is notably larger than that of PolyHeme (Northfield Laboratories Inc., Northfield, IL). The cooperativity coefficient is comparable to that of Hemolink but is lower than other commercial HBOCs. The increased cooperativity of previous HBOCs likely results from the large amounts of tetrameric Hb present in most commercial HBOCs.
3.4 | Size-exclusion chromatography

The average SEC curve of 16 PolyhHb batches is shown in Figure 3. The PolyhHb displays a relatively Gaussian size distribution, indicating uniform MW dispersion. This is further demonstrated by the narrow standard deviation around the average SEC curve. For comparison, the average curve for unmodified hHb is also shown in Figure 3. There is minimal overlap between the hHb curve and the PolyhHb curve demonstrating that the final PolyhHb product contains nearly zero hHb. The primary difference between commercial HBOCs and the one synthesized in this study is their size as determined by MW. Previous PolyhHbs such as Hemopure and PolyHeme contain more than 10% unmodified hHb, which has been shown to cause cell toxicity for hepatocytes. PolyhHbs from this study have an average MW that is five to eight times larger than that of previous commercial HBOCs.

3.4.1 | Spectral deconvolution

Equations (1), (2), and (3) yield Table 3 when calculations are taken out to the fifth polymer order. In this study, sixth-order and larger polymers are not present in the final PolyhHb product as they are retained on the 0.2 μm TFF module during the PolyhHb purification process.

The deconvolution plot of the average PolyhHb SEC curve is shown in Figure 4 to provide a visual representation of how the SEC deconvolution function fits the various polymer order normal curves to the total SEC data. As is evident both visually by the fit as well as the R-squared value, 0.99996, curve fitting the Hb polymer orders describes the overall HPLC-SEC curve very well.

This deconvolution process was applied to all PolyhHbs synthesized in this study. The results are shown in Figure 5. It should be noted that only 4.6% of the average PolyhHb synthesized was comprised of polymeric Hb species less than 500 kDa, which has traditionally been the highest MW reported for previous generation HBOCs. As discussed previously, this reduction in low MW Hb species should mitigate many of the negative side effects associated with prior HBOCs.

3.5 | Auto-oxidation

Prior literature has demonstrated that Hb oxidizes in a first-order manner. Using this information, the ferrous Hb concentration as a function of time was linearized by taking the natural logarithm of concentration as shown in Figure 6. The auto-oxidation rate for 30:1 T-state PolyhHb was less than half of that for Hb. This results from the size difference of PolyhHb compared to Hb. The
larger size of 30:1 T-state PolyHb creates more steric hindrance for O₂ to bind to the heme pocket. This shielding effect may prevent oxidation from happening as quickly compared to hHb. Additionally, the 30:1 T-state PolyHb was stored in modified Ringer’s lactate, which contains NALC. NALC is a reducing agent that was specifically added to the solution to prevent Hb oxidation. While the test samples were diluted in PBS, there was still residual Ringer’s lactate present in solution to slow metHb formation.

The lower auto-oxidation rate constant of 30:1 T-state PolyHb compared to unmodified Hb indicates it may be suitable for extended use in an HF bioreactor. By maintaining the heme iron in the ferrous state, it will be able to bind and release O₂ as intended for a sustained period of time. With a lower k₉₅ value, the PolyHb perfusate will remain functional for a longer duration in the perfusion circuit. This will maintain the intended O₂ gradient across the HF hepatic bioreactor for a longer duration and will require fewer replacements of the perfusion solution.

### 3.6 Simulated bioreactor

The effect of cell density on the combined hypoxic and hyperoxic fraction at various single capillary system radii, PolyHb concentrations, and pO₂,in values is shown in Figure 7. At all system radii, there is an optimal point with minimized hypoxic and hyperoxic conditions. Decreasing the system radius facilitates higher viable cell densities. Increasing the pO₂,in from 70 to 90 mmHg results in larger regions of hypoxia and hyperoxia even at optimized cell densities. Increasing the PolyHb concentration leads to curves with reduced hypoxia/hyperoxia at higher cell densities. This implies that using higher PolyHb concentrations is one strategy for increasing the maximum viable cell density in a preexisting bioreactor.

The relationship between the theoretical Damköhler number and the combined hypoxic and hyperoxic fraction is shown in Figure 8. For the three pO₂,in values, the trends observed are the same. Theoretical Damköhler values at the extrema led to low zonation. A theoretical Damköhler value between 1 and 8 minimizes the combined hypoxic and hyperoxic fraction. Theoretical Damköhler values outside this range lead to nonviable reactor configurations. This suggests that
if the theoretical Damköhler number can be calculated, it has the potential to strongly predict bioreactor performance. Due to the difficulty in its measurement, further analyses will be performed using the practical Damköhler number, which can be easily measured during bioreactor operation.

The relationship between the practical Damköhler and Sherwood number at three different pO$_2$ values and PolyhHb concentration of 12.5 mg/ml is shown in Figure 9. Shaded points correspond to viable bioreactor configurations with a combined hypoxic and hyperoxic volume fraction of less than 0.05. Increasing cell density is correlated with a higher Sherwood number. The Sherwood number itself appears to have little effect on the performance of the bioreactor since both low and high Sherwood values can lead to viable bioreactor conditions. By contrast, low and high practical Damköhler numbers tend to perform poorly. These trends hold at all inlet partial pressure conditions. Overall, the practical Damköhler number may also be predictive of the viability of the bioreactor.

The effect of the practical Damköhler number on the combined hypoxic and hyperoxic fraction is evident in Figure 10. Practical Damköhler numbers between 0.5 and 8 are necessary but not sufficient to minimize the combined fraction. Very low practical Damköhler numbers tend to lead to nonviable reactors with poor zonation. Very high practical Damköhler numbers also lead to nonviable reactors but generally offer improved zonation. This suggests that targeting a specific practical Damköhler number range may be beneficial in minimizing hypoxia and hyperoxia.

In comparison to the theoretical Damköhler number analyzed in Figure 8, the practical value follows a similar but not identical trend. The primary difference is that operating within the optimum range of the theoretical Damköhler number provides a higher probability of
producing a viable bioreactor configuration. The practical Damköhler number is not as predictive of zonation score with the optimum range still potentially leading to bioreactor configurations with large amounts of hypoxia and hyperoxia.

The effect of the Damköhler number on the zonation score when the data are filtered for viable bioreactor configurations is displayed in Figure 10. At 80 and 90 mmHg, higher zonation occurs at the upper edge of the viable range. The data at 100 mmHg are limited but shows that significant zonation is possible at lower Damköhler numbers as well. This suggests a very narrow margin of error when seeking to maximize zonation while maintaining bioreactor viability.

FIGURE 8  Hypoxic and hyperoxic fraction versus theoretical Damköhler number at (a) 80 mmHg, (b) 90 mmHg, and (c) 100 mmHg for a bioreactor supplemented with T-state PolyHb. The PolyHb concentration was 12.5 mg/ml with system radius, fiber length, flow rate, and cell density varying from 0.3–0.7 mm, 0.03–0.9 m, 0.05–0.7 ml/min, and $1 \times 10^7$–$1 \times 10^9$ cells/ml, respectively

The correlation between the zonation score and the volume fraction of each zone in the bioreactor ECS is shown in Figure 11. All points correspond to viable bioreactor configurations with a combined hypoxic and hyperoxic fraction of less than 0.05. Low zonation scores are primarily characterized by the presence of two zones with one dominating the other. The three remaining zones are usually present in negligible amounts. A zonation score of 4.5 is the point at which a third zone appears and a zonation score of 5 signifies the point at which all three zones occupy nontrivial volume fractions of the ECS.

FIGURE 9  Practical Damköhler number versus Sherwood number at (a) 80 mmHg, (b) 90 mmHg, and (c) 100 mmHg for a bioreactor supplemented with T-state PolyHb. The PolyHb concentration was 12.5 mg/ml with system radius, fiber length, flow rate, and cell density varying from 0.3–0.7 mm, 0.03–0.9 m, 0.05–0.7 ml/min, and $1 \times 10^7$–$1 \times 10^9$ cells/ml, respectively. Values with hypoxic/hyperoxic fractions less than 5% of the total volume are circled
Above this point, two of the three zones start approaching parity with each other while the third zone remains as a relatively smaller region. Therefore, a zonation score of 5 can be regarded as a reasonable threshold for optimal zonation.

The false discovery rate (FDR) Log Worth plot of the combined hypoxic and hyperoxic volume fraction is shown in Figure 12a. All parameters have at least minor effects with cell density and system radius having the largest impact. The fiber length and flow rate have similar effects with pO₂ₖ and PolyhHb concentration being close as well.

The FDR Log Worth plot of the Sherwood number is shown in Figure 12b. The system radius and cell density have the strongest correlation while pO₂ₖ and the PolyhHb concentration have the lowest effect. The fiber length and flow rate have similar effects in the middle.

The FDR Log Worth plot of the Damköhler number is shown in Figure 12c. Here, the fiber length and flow rate have the strongest correlation while pO₂ₖ has the lowest effect. The system radius, PolyhHb concentration, and cell density have relatively similar impacts.

The FDR Log Worth plot of the zonation score is displayed in Figure 12d. The cell density and pO₂ₖ have the largest effects while

![Figure 10](image.png)

**Figure 10** Effect of the practical Damköhler number on the (a) hypoxic + hyperoxic fraction and (b) zonation for a bioreactor supplemented with T-state PolyhHb. For each plot inlet, partial pressures of 100 mmHg (top), 90 mmHg (middle), and 80 mmHg (bottom) are shown. The PolyhHb concentration was 12.5 mg/ml with system radius, fiber length, flow rate, and cell density varying from 0.3–0.7 mm, 0.03–0.9 m, 0.05–0.7 ml/min, and 1 × 10⁷ – 1 × 10⁹ cells/ml, respectively.

![Figure 11](image.png)

**Figure 11** Category plot of volume fraction and zonation for a bioreactor supplemented with T-state PolyhHb. The PolyhHb concentration was 12.5 mg/ml while system radius, pO₂ₖ, and cell density were fixed at 0.62 mm, 80 mmHg, and 1 × 10⁷ cells/ml, respectively. Fiber length and flow rate varied between 0.1–0.2 m and 0.03–0.3 ml/min.
PolyhHb concentration and flow rate have similar, smaller impacts. The system radius and fiber length both have the lowest correlation with zonation.

Overall, the cell density consistently had a fairly large impact on the four quantities while pO2,in and the PolyhHb concentration generally had smaller effects.

**CONCLUSIONS**

Previous HBOCs failed to pass clinical trials due to safety complications attributed to significant amounts of low MW Hb species in solution. The PolyhHb synthesized in this study was purified to minimize the concentration of low MW Hb species in the final product, improving the safety of these materials for use in bioreactor circuits. Furthermore, the rate of auto-oxidation over a 24 hr time period was found to decrease after chemical cross-linking. This advancement will allow 30:1 T-state PolyhHbs to retain a large portion of their O2 carrying capacity during bioreactor perfusion and enhance O2 transport. Additionally, a program was designed to determine the polymeric composition of PolyhHbs and determine the size of various fractions. Using this program, we can verify the minimal presence of low MW Hb species, while simultaneously calculating the MW distribution of PolyhHb.

This study also shows that zonation in a bioreactor can be reasonably quantified via computational modeling. Furthermore, the Damköhler number may predict zonation as well as hypoxic and hyperoxic performance in a hepatic HF bioreactor. This may potentially aid in the optimal design and operation of such a bioreactor. Additional experimental work is needed to validate these computational findings and determine their application to real-world systems.

**ACKNOWLEDGMENTS**

We acknowledge Dr. James Lee (Chemical and Biomolecular Engineering, The Ohio State University) for allowing the use of his dynamic light scattering (DLS) spectrometer, and Marni Grevenow (Transfusion Services, Wexner Medical Center, The Ohio State University) for generously donating expired human RBC units. This work was supported by The Department of Defense Grant W81XWH-18-1-0059 as well as National Institutes of Health Grants R01HL126945, R01HL138116, and R01EB021926.

**ORCID**

Clayton Cuddington 🐥 [https://orcid.org/0000-0001-8739-2155](https://orcid.org/0000-0001-8739-2155)

Donald Belcher 🐥 [https://orcid.org/0000-0002-7633-6219](https://orcid.org/0000-0002-7633-6219)

Niral Ramesh 🐥 [https://orcid.org/0000-0001-9649-1665](https://orcid.org/0000-0001-9649-1665)

**REFERENCES**

1. Eghbali H, Nava MM, Mohebbi-Kalhori D, Raimondi MT. Hollow fiber bioreactor technology for tissue engineering applications. *Int J Artif Organs*. 2016;39:1-15.
2. Hirschel M, Gangemi JD, McSharry J, Myers C. Novel uses for hollow fiber bioreactors. *Genet Eng Biotechnol News*. 2011;31:42-44.
3. Gordon J, Dare MR, Palmer AF. Engineering select physical properties of cross-linked red blood cells and a simple a priori estimation of their efficacy as an oxygen delivery vehicle within the context of a hepatic hollow fiber bioreactor. *Biotechnol Prog*. 2005;21:1700.
4. Chen G, Palmer AF. Hemoglobin-based oxygen carrier and convection enhanced oxygen transport in a hollow fiber bioreactor. *Biotechnol Bioeng*. 2009;102:1603-1612.
5. Jones JA. Red blood cell substitutes: current status. *Br J Anaesth*. 1995;74:697-703.
24. Palmer AF, Sun G, Harris DR. The quaternary structure of tetrameric hemoglobin. Antioxid Redox Signalng. 2004;6:657-666.

25. Alayash AI. Hemoglobin-based blood substitutes and the treatment of sickle cell disease: more harm than help? Biomolecules. 2017;7:16-28.

26. Winterbourn CC. Oxidative reactions of hemoglobin. Expert Opin Biol Ther. 2007;7:665-675.

27. Alayash AI. Hemoglobin-based blood substitutes and the treatment of sickle cell disease: more harm than help? Biomolecules. 2007;7:16-28.

28. Hill AV. Proceedings supplement: the possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol. 1910;40:iv-vii.

29. Jahr JS, MacKenzie C, Pearce LB, Pitman A, Greenburg AG. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma Infect Crit Care. 2008;64:1484-1497.

30. LaMuraglia GM, O’Hara PJ, Baker WH, et al. The reduction of the allo genic transfusion requirement in aortic surgery with a hemoglobin-based solution. J Vasc Surg. 2000;31:299-308.

31. Napoliello LM. Hemoglobin-based oxygen carriers: first, second or third generation? human or bovine? Where are we now? Crit Care Clin. 2009;25:279-301.

32. Catt Kajmer CJ, Allen AC, Campbell JA, et al. A phase I study of oxidized raffinose cross-linked human hemoglobin. Crit Care Med. 2000;28:2283-2292.

33. Faivre B, Menu P, Labrude P, Vigneron C. Hemoglobin autooxidation/oxidation mechanisms and methemoglobin prevention or reduction processes in the bloodstream: literature review and outline of autooxidation reaction. Artif Cells Blood Substit Immobil Biotechnol. 1998;26:17-27.

34. Xu H, Bjerneld EJ, Käll M, Börjesson L. Spectroscopy of single hemoglobin molecules by surface enhanced Raman scattering. Phys Rev Lett. 1999;83:4357-4360.

35. Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol. 2010;50:323-354.

36. Laskowski RA, Gerick F, Thornton JM. The structural basis of allosteric regulation in proteins. FEBS Lett. 2009;583:1692-1698.

37. Palmer AF, Zhang N, Zhou Y, Harris DR, Cabrales P. Small-volume resuscitation from hemorrhagic shock using high-molecular-weight tense-state polymerized hemoglobin. J Trauma Infect Crit Care. 2011;71:798-807.

38. Day TK. Current development and use of hemoglobin-based oxygen-carrying (HBOC) solutions. J Vet Emerg Crit Care. 2003;13:77-93.

39. Larsen R, Gozzelino R, Jeney V, et al. A central role for free heme in the pathogenesis of severe sepsis. Sci Transl Med. 2010;2:1-12.

40. Smith A, McCullough RJ. Hemopexin and haptoglobin: allies against heme toxicity from hemoglobin not contenders. Front Physiol. 2015;6:148.

41. Tsuruga M, Matsuoka A, Hachimori A, Sugawara Y, Shikama K. The molecular mechanism of autoxidation for human oxyhemoglobin. Tilting of the distal histidine causes nonequivalent oxidation in the β chain. J Biol Chem. 1998;273:8607-8615.

42. Jia Y, Wood F, Menu P, Faivre B, Caron A, Alayash AI. Oxygen binding and oxidation reactions of human hemoglobin conjugated to carboxylic dextran. Biochim Biophys Acta - Gen Subj. 2004;1672:164-173.

43. Meng F, Kassa T, Jana S, et al. Comprehensive biochemical and physicochemical characterization of hemoglobin-based oxygen carrier therapeutic: all HBOCs are not created equally. Bioconjug Chem. 2018;29:1560-1575.

44. Buehler PW, Boykins RA, Jia Y, Norris S, Freedberg DI, Alayash AI. Structural and functional characterization of glutaraldehyde-polymerized bovine hemoglobin and its isolated fractions. Anal Chem. 2005;77:3466-3478.

45. Ali AA, Ali GS, Steinke JM, Shepherd AP. Co-oxidation interference by hemoglobin-based blood substitutes. Anesth Analg. 2001;92:863-869.

How to cite this article: Cuddington C, Moses S, Belcher D, Ramesh N, Palmer A. Next-generation polymerized human hemoglobins in hepatic bioreactor simulations. Biotechnol Progress. 2020;36:e2958. https://doi.org/10.1002/btpr.2958